ICI 200880Alternative Names: ICI200880
Latest Information Update: 07 Apr 1999
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Anti-ischaemics; Surfactants
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Cystic fibrosis; Emphysema; Myocardial ischaemia